Browsing by Subject "Aortic valve replacement"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Impact of sarcoidosis in patients undergoing aortic valve replacement: Insight from nationwide readmission database 2016-2019
    (Elsevier, 2025) Patel, Kunal N.; Bajaj, Suryansh; Majmundar, Monil; Majmundar, Vidit; Agrawal, Ankit; Zala, Harshvardhan; Doshi, Rajkumar; Singh, Karandeep; Kaur, Avleen; Patel, Vyoma N.; Gonuguntla, Karthik; Sattar, Yasar; Kalra, Ankur; Medicine, School of Medicine
    It is not well-known if valve replacement outcomes differ in patients with sarcoidosis, especially in aortic valve intervention, where the pressure gradients are physiologically high. In this retrospective study, we included all patients who underwent surgical/transcatheter aortic valve replacement from the Nationwide Readmission Database (2016-2019), and then divided them into those with and without sarcoidosis. Logistic and cox proportional hazard regression models were used. In-hospital mortality, stroke, acute kidney injury, paravalvular leak, 30-day pacemaker implantation, and 30-day heart failure readmission were similar in patients with and without sarcoidosis. Thus, sarcoidosis did not affect the clinical outcomes in patients undergoing aortic valve replacement. Further prospective studies are needed in this patient subgroup to support clinical decision-making.
  • Thumbnail Image
    Item
    MAGGIC, STS, and EuroSCORE II Risk Score Comparison After Aortic and Mitral Valve Surgery
    (Elsevier, 2021) Zhuo, David X.; Bilchick, Kenneth C.; Shah, Kajal P.; Mehta, Nishaki K.; Mwansa, Hunter; Nkanza-Kabaso, Kanasa; Kwon, Younghoon; Breathett, Khadijah K.; Hilton-Buchholz, Ebony J.; Mazimba, Sula; Medicine, School of Medicine
    Objectives: To compare the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score with the established Society of Thoracic Surgeons (STS) and EuroSCORE II risk prediction models regarding mortality discrimination after aortic and mitral valve surgery. Design: Retrospective cohort study. Setting: Single tertiary academic medical center. Participants: A total of 259 patients who underwent open aortic valve replacement or open mitral valve repair/replacement from 2009-2014. Interventions: Retrospective chart review. Measurements and main results: MAGGIC, STS, and EuroSCORE II risk scores for each patient were studied using binary logistic regression and receiver operating characteristic analysis for the primary endpoint of one-year mortality and secondary endpoint of 30-day mortality. One-year mortality C-statistics were similar across risk scores (STS 0.709, 95% confidence interval [CI] 0.578-0.841; MAGGIC 0.673, 95% CI 0.547-0.799; EuroSCORE II 0.642, 95% CI 0.521-0.762; p = 0.56 between STS and MAGGIC; p = 0.20 between STS and EuroSCORE II; and p = 0.69 between MAGGIC and EuroSCORE II). Thirty-day mortality C-statistics also were similar between STS (0.797, 95% CI 0.655-0.939; p < 0.0001 v null hypothesis), MAGGIC (0.721, 95% CI 0.581-0.860; p = 0.33 v STS), and EuroSCORE II (0.688, 95% CI 0.557-0.818; p = 0.06 v STS; p = 0.68 v MAGGIC). Conclusions: The MAGGIC risk score performs similarly to STS and EuroSCORE II risk models in mortality discrimination after aortic and mitral valve surgery, albeit in a small sample size. This finding has important implications in establishing MAGGIC as a viable prognostic model in this population subset, with fewer variables and ease of use representing key advantages over STS and EuroSCORE II.